CN102060882B - Dehydrogenated clindamycin phosphate, analysis preparation method and application thereof - Google Patents
Dehydrogenated clindamycin phosphate, analysis preparation method and application thereof Download PDFInfo
- Publication number
- CN102060882B CN102060882B CN200910198984.8A CN200910198984A CN102060882B CN 102060882 B CN102060882 B CN 102060882B CN 200910198984 A CN200910198984 A CN 200910198984A CN 102060882 B CN102060882 B CN 102060882B
- Authority
- CN
- China
- Prior art keywords
- clindamycin phosphate
- impurity
- moving phase
- retention time
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses dehydrogenated clindamycin phosphate and an analysis preparation method thereof. The analysis preparation method is used for analyzing raw materials of clindamycin phosphate, and separating and preparing the dehydrogenated clindamycin phosphate from the clindamycin phosphate. The analysis preparation method comprises the following steps of: a) measuring the raw materials of the clindamycin phosphate by a liquid chromatography/mass spectroscopy (LC-MS) method; determining the dehydrogenated clindamycin phosphate in the raw materials according to the relative retention time and/or the molecular weight of analyzed components; and b) determining the conditions of a preparative chromatography method according to chromatographic retention behaviors displayed by the relative retention time of the dehydrogenated clindamycin phosphate in the step a), and collecting the analyzed components corresponding to the relative retention time by the preparative chromatography method.
Description
Technical field
The present invention relates to analytical chemistry field, relate in particular to pharmaceutical analysis chemical field, particularly the impurity dehydrogenation Clindamycin Phosphate of Clindamycin Phosphate and analysis and preparation method.
Background technology
Clindamycin Phosphate is in vitro without anti-microbial activity, after entering in body, under the effect of phosphoesterase, be hydrolyzed to rapidly clindamycin, change in vivo the N-demethyl clindamycin with strong anti-microbial activity, Main Function is in the 50S of bacterial ribosome subunit, thereby stop the prolongation of peptide chain and disturb the synthetic of DNA of bacteria and bacterioprotein, still A albumen and the fine hair shape coat that can remove bacterium surface, make bacterium easily be engulfed and kill.Clindamycin Phosphate mainly has very strong anti-microbial activity to gram-positive cocci and anerobe, its effect and purposes are similar to clindamycin hydrochloride, but absorb rapidly, and effect is lasting, Plasma Concentration, compared with the high twice of hydrochloride, is a Broad spectrum antibiotics that has anaerobe resistant and aerophil effect concurrently.Have in the market aqueous injection, infusion solution, injection, aseptic subpackaged powder injection, lyophilized injectable powder etc., clinical application be take injection as main.
Any material that affects pharmaceutical purity is all called impurity, and generally speaking, impurity refers to other chemical substances beyond the medicine of introducing in production and storage process or producing.Impurity in drug standard refers to according to through relevant drug regulatory department of country in accordance with the law in the regulation technique of examination and approval and the medicine of regulation supplementary material production, the impurity of being brought into by its production technique and supplementary material, or the degraded product producing in storage process of confirming through stability experiment.Impurity in drug standard does not comprise change production technique or change supplementary material and the new impurity that produces does not comprise the foreign matter that infiltrates or pollute yet.Drug manufacturing enterprise's change production technique or supplementary material, and bring thus the revision of new impurity to proper mass standard into, all should to relevant drug regulatory department, declare to approve in accordance with the law.
The impurity of medicine is generally relevant with specific medicine, comes from the following aspects:
1. stem from drug production process the lyase that generally uses, catalyzer etc.;
2. react reaction raw materials incomplete and that exist, the materials relevant to building-up process such as reaction initial recombination thing, synthetic mesophase product, byproduct;
3. the oxidation in storage process, decomposition, hydrolysate;
4. the optical isomer in chipal compounds;
5. the multiple crystal formation of medicine;
In animals and plants medicine extract except the small molecules such as effective constituent alkaloid volatile oil, organic acid, also there is the impurity such as the protein that molecular weight is larger, the matter of trampling on, starch, resin;
7. radiate the decay material in medicine;
8. the protein of unconventionality expression in bioengineering product;
9. heavy metal and inorganic salt.
Impurity of the drug can be divided into by chemical classes and characteristic: organic impurity, inorganic impurity, volatile organic impurity.By sources can be divided into: related substance (precursor, intermediate, by product and the degraded product etc. that comprise chemical reaction), other impurity and tramp material etc.By structural relation, impurity can be divided into again: other steroidals, related alkaloids, geometrical isomer, optical isomer and polymkeric substance etc.By toxicity, can be divided into toxic impurities and common impurities etc. again.Common impurities is under amount the impurity without remarkable bad biological action, and toxic impurities is the impurity with strong bad biological action.
It is the important step that drug quality is controlled that impurity detects, and the assay in the middle of drug quality refers to the content of main component in bulk drug and preparation, and related substance refers to the organic impurity in the middle of bulk drug and preparation.By related substance, check, understand fully source, character, the detection method of related substance and limit the quantity of, can optimize the factors such as synthetic route, experiment condition, and then avoid it to produce related substance or it drops to bottom line, guarantee from many aspects and improve drug quality, reducing the untoward reaction of medicine.
Impurity of the drug checks that analytical procedure should be sensitive, exclusive.Along with scientific and technical progress, the improving constantly of separated, analysis means, the detection method of impurity of the drug has obtained continuous improvement.The method of detection of drugs impurity is a lot, can carry out preferably separation, identify the impurity of medicine, as high performance liquid chromatography, gas-chromatography, ultraviolet, infrared spectra, thin-layer chromatographic analysis, capillary zone electrophoresis, thin layer capillary electrophoresis etc., these analytical procedures are widely used in content of drug mensuration and impurity detects.In recent years, mass-spectrometric technique is applied increasingly extensive aspect impurity of the drug analysis, and gas-chromatography coupling technology, liquid chromatography coupling technique have become the important means that impurity of the drug is analyzed.
Impurity research in exploitation new raw material medicine and new preparation process, the requirement that should declare in strict accordance with the relevant new drug of country is studied, also can study with reference to text Q3A (impurity in new raw material medicine) and the Q3B (impurity in new preparation) of ICH, and the security of impurity and degraded product are carried out to safety evaluation.Its specific requirement following points:
1. pair in esse impurity and potential impurity in synthetic, purifying and storage, should adopt effective method for separating and analyzing to detect;
For apparent content 0.1% and above impurity and apparent content in the impurity with strong biological action below 0.1% or toxic impurities, give qualitative or confirm its structure;
3. pair degraded product occurring in stability test, also should study by above-mentioned requirements;
4. the determination of foreign matter project in new drug quality standard should comprise after deliberation with study on the stability and detecting, and the impurity occurring in batch production and degraded product, and comprises corresponding limit;
5. except degraded product and toxic impurities, the impurity of having controlled in bulk drug is generally no longer controlled in preparation;
6. the inorganic impurity in bulk drug and preparation, should determine inspection item according to its production technique, starting raw material situation, but for toxic inorganic impurity, should in quality standard, stipulate its check item.
In the research and production of imitation medicine, as different from original development medicine in the kind of finding impurity or different with existing legal impurity, must increase new impurity item inspection item, should study in strict accordance with aforesaid method, declare new drug standard or proper mass standard is revised, and reporting relevant drug regulatory department to examine.
The isomer coexisting and microbiotic polycomponent, generally not as determination of foreign matter project, as coexisting substances, are stipulated its ratio if desired in quality standard, the consistence with the bulk drug that guarantees to produce use when declaring registration.But when the material when coexisting is toxic impurities, this material is just no longer thought coexisting substances.Single enantiomer medicine, its can compatible other enantiomorphs should be as determination of foreign matter.Racemization medicine when having the official quality standands of its single enantiomer medicine, should be established specific rotation inspection item in the quality standard of this raceme.
Volatile organic impurity, should, according to organic solvent used and residual condition thereof in production technique, determine inspection item.Can the requirement about volatile organic impurity with reference to Chinese Pharmacopoeia, or with reference to ICH text Q3C (residual solvent governing principle).To residual toxic solvents, should stipulate its inspection item.
In order to guarantee drug safety, each impurity in bulk drug/preparation must carry out safety evaluation and that is to say the necessary limit of impurities that guarantees security of setting up, ICH criterion requires: in medicine, the limit of impurity is 0.1% (lower to drug toxicity limit), all unknown impurities higher than this level should identify, and the more important thing is, all impurity higher than 0.1% should be studied its toxicity.ICH, in " impurity in new raw material medicine " governing principle of revision on February 7th, 2007, is divided into two classes according to maximal dose every day of bulk drug by bulk drug, and has formulated respectively report threshold value, evaluation threshold value and the reasonable limit of impurity.Report threshold value wherein refers to that all impurity higher than this threshold value and content all should charge in the survey report of every batch of product, and reaction is in declaration material.And identify that threshold value refers to that all impurity higher than this threshold value all tackles its structure and confirm.Reasonable limit refers to as long as the limit of impurities of formulating in quality standard, not higher than this limit, just does not need to provide the formulation foundation of this limit, all thinks that this limit is rational.
For new preparation, ICH has also done clearly regulation in " impurity in new preparation " governing principle of revision on February 5th, 2003, and this governing principle has been worked out report threshold value, evaluation threshold value and the reasonable limit of impurity equally according to different dosages.
Medicine competent authorities of European Union require manufacturing enterprise: (1) should set up the limit of unknown impuritie (0.1%) in stability study; 2) reply limit is more than or equal to 0.1% unknown impuritie and carries out structure and determine and security verification.For some antibiotics, require higher, leavened prod erythromycin for example, this kind EP is recorded, and the limit ignored of regulation impurity is 0.06%, and any impurity must not surpass 3.0%.The requirement of medicine competent authorities of European Union, any unknown peak that can ignore limit 0.06% that is greater than gives structure and determines and propose suitable limit of impurities suggestion, when impurity reaches this limit, it is carried out to safety evaluation.FDA also especially pays close attention to the purity of drug manufacture Chinese traditional medicine and the security of dosage, requires pharmaceutical production person comprehensively to analyze impurity, and more structural information is provided as much as possible.Conventionally, over 0.1% impurity, need identify out and carry out quantitative analysis by the good method of selectivity, and 0.01%～0.1% impurity is also represented to keen interest.
Although determining of limit of impurities is extremely important for drug research and development, it is optimistic that the reality of domestic drug research and development is not made us.From new drug in recent years, declare situation analysis, in the research of impurity and limit, exist more problem aspect determining, main manifestations is: Some Drugs research unit does not know much have less understanding to the importance of impurity research; Comprehensive and accurate not to the control of impurity in standard; While working out limit of impurities, consider a problem comprehensive not, seldom consider the detrimentally affect of impurity to drug safety; Even when the content of impurity obviously exceeds the scope that normal process allows, do not note present prescription and technique to carry out necessary optimization, to reduce the limit of impurity yet.
< < Chinese Pharmacopoeia > >, < < American Pharmacopeia > >, < < European Pharmacopoeia > > and < < British Pharmacopoeia > > all have recording of Clindamycin Phosphate related substances item, and recording of < < British Pharmacopoeia > > and < < European Pharmacopoeia > > is more comprehensive, < < British Pharmacopoeia > > and < < European Pharmacopoeia > > have recorded lincomycin according to the degradation pathway of production technique and Clindamycin Phosphate at " possible impurity " item, clindamycin B2-phosphoric acid ester, clindamycin 3-phosphoric acid ester, five impurity of clindamycin 4-phosphoric acid ester and clindamycin.
In < < Chinese Pharmacopoeia > >, Clindamycin Phosphate is only limited the total amount of impurity, not concrete to single contaminant research, and medicine competent authorities of European Union and FDA all require apparent content 0.1% and above impurity thereof in Clindamycin Phosphate bulk drug, carry out Structural Identification and security verification.
Summary of the invention
The object of the invention is the impurity of Clindamycin Phosphate bulk drug to study, and is mainly that separation prepares the standard substance of impurity and identify the impurity structure in bulk drug.The method according to this invention to the impurity in bulk drug analyze, preparation and Structural Identification, can and illustrate untoward reaction mechanism for the toxicologic study of impurity basis is provided, also can provide reference for the selection of technique compound experiment condition, be conducive to the control of production process Quality Evaluation of Chinese Medicinal amount simultaneously.
According to a first aspect of the invention, it provides as shown in the formula the dehydrogenation Clindamycin Phosphate shown in I:
According to a second aspect of the invention, it provides analysis and the preparation method of the dehydrogenation Clindamycin Phosphate as described in first aspect of the present invention, the method is for analyzing Clindamycin Phosphate raw material, and therefrom described dehydrogenation Clindamycin Phosphate is prepared in separation, comprises the following steps:
A) by LC-MS method, measure described Clindamycin Phosphate raw material, according to the relative retention time of analyzed composition and/or molecular weight, determine the dehydrogenation Clindamycin Phosphate in described raw material;
B) according to step, the shown chromatogram retention behavior of relative retention time of the dehydrogenation Clindamycin Phosphate described in a) is determined the condition of preparative chromatography, by preparative chromatography, collects and analyzed composition corresponding to described relative retention time.
Preferably, to measure the moving phase pH value adopting be 4.00～5.00 to the LC-MS method of step described in a); It is 20 ℃～40 ℃ that described LC-MS method is measured the column temperature adopting; Described LC-MS method is measured the moving phase adopting and is comprised 15%～25% acetonitrile; Described LC-MS method is measured the moving phase adopting and is comprised 0.1%～0.3% ammoniacal liquor.
More preferably, the LC-MS method of step described in a) measured the HPLC condition that adopts and is:
Moving phase 20% acetonitrile, 0.1% ammoniacal liquor;
PH formic acid is adjusted pH to 4.90;
25 ℃ of column temperatures;
Flow velocity 1.0ml/min;
Detect wavelength 210nm;
Chromatographic column Diamonsil ODS C18,5 μ m, 250 * 4.6mm post.
The method according to this invention, step b) the preparative chromatography institute employing condition described in comprises: moving phase 15%～25% acetonitrile, 0.1～0.3% ammoniacal liquor; PH formic acid is adjusted pH to 4.00～5.00; Column temperature: 20 ℃～40 ℃; Chromatographic column Waters μ Bondapak ODS C18,5 μ m, 7.8mm * 300mm post, or Agela Venusil ODS XBP C18,5 μ m, 10mm * 250mm post.
Preferably, the preparative chromatography institute employing condition step b) is:
Moving phase 22% acetonitrile, 0.1% ammoniacal liquor;
PH formic acid is adjusted pH to 4.00;
Flow velocity 1.0ml/min;
Detect wavelength 210nm;
Chromatographic column Agela Venusil ODS XBP C18 post, 5 μ m, 10mm * 250mm post;
Sample size 120 μ l;
Collecting retention time is the corresponding assay in peak of locating for 20.220 minutes.
According to a third aspect of the present invention, it provides dehydrogenation Clindamycin Phosphate as described in the first aspect present invention purposes for the preparation of medicament for resisting gram-positive bacteria.
Preferably, described gram-positive microorganism comprises anti-Bacillus subtilus and streptococcus aureus.
According to a third aspect of the present invention, it provides the impurity standard substance that described in second aspect prepared by method according to the present invention, it is characterized in that, described impurity has aforementioned structural formula I.
According to a fourth aspect of the present invention, it provides impurity standard substance as described in third aspect present invention for analyzing the purposes of Clindamycin Phosphate raw material.
Accompanying drawing explanation
The accompanying drawing providing in conjunction with the application, will be easier to understand the application's other features, objects and advantages.These accompanying drawings only, for demonstration, do not form any restriction to the present invention.
Fig. 1 is for investigating pH value and the resolution graph of a relation under different numerical value in LC-MS method conditioning process;
Fig. 2 is the column temperature under different numerical value and the graph of a relation of resolution in investigation LC-MS method conditioning process;
Fig. 3 is for investigating acetonitrile ratio and the main peak retention time graph of a relation under different numerical value in LC-MS method conditioning process;
Fig. 4 is for investigating ammoniacal liquor ratio and the main peak retention time graph of a relation under different numerical value in LC-MS method conditioning process;
Fig. 5 is for investigating ammoniacal liquor ratio and the resolution graph of a relation under different numerical value in LC-MS method conditioning process.
Embodiment
In order to understand better technical scheme of the present invention, below in conjunction with the specific embodiment of the present invention, technical scheme of the present invention is described further, but it does not limit the present invention.
The bulk drug of the same name that the Clindamycin Phosphate raw material that present embodiment is used all adopts Zhejiang Province Tiantai Pharmaceutical Co., Ltd to provide.
lC-MS measures Clindamycin Phosphate bulk drug
In order to study Clindamycin Phosphate bulk drug impurity, utilize LC-MS instrument to study the major impurity of bulk drug, object is in order to determine molecular weight and the chromatogram retention behavior of impurity.
In Clindamycin Phosphate molecular structure, there is acidic-group, also have basic group, belong to the material of both sexes.In pharmacopoeia of each country, HPLC detects and all selects ion suppression chromatography (ion suppression chromatography, ISC) to analyze.The mass spectrograph of selecting due to present embodiment is electron spray(ES) (electrospray ionization; ESI) ionization mode; in order to reduce ion pair inhibitor to the impact of measuring, also in order to protect instrument, present embodiment adopts volatile ammoniacal liquor, formic acid buffering salt system to detect.Owing to there is no conjugated structure in Clindamycin Phosphate molecule, and contain N, O, S heteroatoms, in molecule, the probability of valence electron n-σ * transition is higher, so molecular end absorption is more intense, selects 210nm as detecting wavelength.First moving phase select 20% acetonitrile, investigates pH value to the impact of measuring.
The selection of moving phase pH value
Instrument is HP1100, and chromatographic column Diamonsil ODS C18 (5 μ m, 250 * 4.6mm) post detects wavelength 210nm, 25 ℃ of column temperatures, and flow velocity 1.0ml/min, detects wavelength 210nm.Take the buffered soln that Clindamycin Phosphate bulk drug is dissolved in 20% acetonitrile pH value 4.00, be configured to the solution of 20mg/ml, sample size 20 μ l.Configure the moving phase of a plurality of pH values, measure respectively.
In the present embodiment, having investigated moving phase pH value is the situation of 4.00,4.50,4.75,4.90,5.00 o'clock HPLC mensuration bulk drugs, when moving phase pH value is increased to 5.00 by 4.00, the ratio that Clindamycin Phosphate converts molecularity to by ionic condition increases, component solubleness in stationary phase increases, capacity factor increases, and the retention time of main peak increases along with increasing of pH value.During moving phase pH value 4.00, can only measure 4 impurity, than the moving phase of other four pH is few, measure an impurity, therefore, the method is not suitable as the condition of measuring bulk drug.According to retention time ascending by six peaks in color atlas compile be successively the 1st peak, the 2nd peak ... the 6th peak, wherein main peak is the 5th peak, there is no the 4th peak during moving phase pH value 4.00.
Fig. 1 is pH value and resolution graph of a relation, and as can be seen from the figure, the resolution of moving phase pH value major effect the 3rd peak and the 4th peak, the 4th peak and main peak, to having the greatest impact of the resolution of the 4th peak and main peak.During moving phase pH value 4.50, than moving phase pH, be worth 4.00 o'clock, occur a small peak (the 4th peak, retention time 17.307min) before main peak, but peak shape be very poor, chromatographic peak symmetrical factor approaches 0.During moving phase pH value 4.75, the retention time at the 4th peak is 18.467min, and peak symmetrical factor is 2.09, and the resolution of main peak is 1.44.During moving phase pH value 4.90, the retention time at the 4th peak is 18.942min, and peak symmetrical factor is 1.264, and the resolution of main peak is 1.55, and it is the situation of 4.75 o'clock that peak shape and resolution are better than moving phase pH.When moving phase pH is 5.00, the retention time at the 4th peak is 19.782min, peak symmetrical factor is 0.77, with the resolution of main peak be 1.97, it is 5.00 o'clock that resolution is better than moving phase pH, but the resolution at the 3rd peak (retention time 18.640min) and the 4th peak is 0.90, and resolution is too low, and during moving phase pH value 4.90, the resolution at two peaks is 1.53.Therefore, consider after two factors of resolution and peak shape moving phase pH value while selecting pH4.90 to measure as bulk drug.
The selection of column temperature
Instrument is the same, and moving phase is selected i.e. 20% acetonitrile of above-mentioned moving phase 4,0.1% ammoniacal liquor, and formic acid is adjusted pH to 4.90, and flow velocity 1.0ml/min detects wavelength 210nm, and sample configuration and sample size are the same.
Fig. 2 is the graph of a relation of column temperature and resolution, 20 ℃, 25 ℃, 30 ℃ and 40 ℃ of four column temperatures in present embodiment, have been selected, investigated the chromatogram retention behavior of bulk drug under the different column temperature of identical moving phase, ascending according to retention time in color atlas, it is the 1st peak, the 2nd peak that 6 peaks are compiled successively ... the 6th peak, main peak is the 5th peak, during 40 ℃ of column temperatures, does not occur the 4th peak in color atlas.In the process that column temperature raises, molecular thermalmotion aggravation, the hydrophobic association effect between solute molecule and the alkyl of Bonded Phase weakens, and in advance, post pressure drop is low for the retention time of main peak.Column temperature does not have the impact of moving phase pH value remarkable on the impact of resolution, during 40 ℃ of column temperatures, has only occurred four impurity in color atlas, than few under other three column temperatures, detects an impurity, and therefore, 40 ℃ are not suitable for as the conditions that detect bulk drug.During 20 ℃ of column temperatures, the 4th peak retention time is 19.678min, and the symmetrical factor of chromatographic peak is 1.841, and the resolution of main peak is 1.39, peak shape and resolution are all not as good as 25 ℃ of column temperatures (the peak symmetrical factor at the 4th peak is 1.264 25 ℃ time, and main peak resolution is 1.55).During 30 ℃ of column temperatures, the resolution of the 4th peak and main peak is 1.62, but the resolution at the peak of the peak of retention time 17.391min and retention time 18.677min only has 1.17.In order to guarantee that all impurity all can be detected, guaranteeing under the prerequisite of resolution, select 25 ℃ of conditions that detect as HPLC.
The selection of organic phase ratio
Instrument, chromatographic column, flow velocity, detection wavelength, sample size are the same, and 25 ℃ of column temperatures configure respectively the moving phase of 15% acetonitrile, 18% acetonitrile, 20% acetonitrile, 25% acetonitrile.
Fig. 3 is acetonitrile ratio and main peak retention time graph of a relation.In the process that the ratio of acetonitrile raises, the polarity of moving phase reduces, and elutive power increases, and the k of solute increases, and retention time in advance.As can be seen from the figure, the retention time of main peak shifts to an earlier date along with the raising of moving phase acetonitrile ratio.The moving phase of four ratio acetonitriles all can detect 5 impurity, but when moving phase is 15% acetonitrile, 18% acetonitrile, analysis time is oversize.When moving phase is 25% acetonitrile, the separation at peak is not ideal enough, is therefore also not suitable for as the HPLC condition detecting.Determine that 20% acetonitrile is proper as the condition of moving phase.
The selection of buffering salt ratio
Instrument, chromatographic column, flow velocity, detection wavelength, sample size are the same, 25 ℃ of column temperatures.Be configured to respectively current downflow phase: 20% acetonitrile, 0.05% ammoniacal liquor, formic acid adjust pH to 4.90; 20% acetonitrile, 0.1% ammoniacal liquor, formic acid adjust pH to 4.90; 20% acetonitrile, 0.2% ammoniacal liquor, formic acid adjust pH to 4.90; 20% acetonitrile, 0.3% ammoniacal liquor, formic acid adjust pH to 4.90.
The same, according to retention time order, 6 peaks are called after the 1st peak, the 2nd peak successively ... the 6th peak.Between ratio major effect the 2nd peak and the 3rd peak of buffering salt, the 3rd peak is in the 4th peak-to-peak resolution.
Result shows, when moving phase ammoniacal liquor ratio is 0.3%, can only detect 4 impurity, and therefore 0.3% ammoniacal liquor is not suitable for as testing conditions.When in moving phase, ammoniacal liquor ratio is 0.05% and 0.2%, the 3rd peak and the 4th peak-to-peak resolution when in moving phase, ammoniacal liquor ratio is 0.1% ammoniacal liquor, are 0.1% as HPLC condition moving phase condition so select ammoniacal liquor ratio.Ammoniacal liquor ratio shown in Figure 4 and main peak retention time graph of a relation, and the ammoniacal liquor ratio shown in Fig. 5 and resolution graph of a relation.
PH value, organic phase ratio, column temperature, buffering salt ratio four factors have more than been examined or check for the impact of retention time and the resolution of impurity in bulk drug, the HPLC condition that present embodiment selects HPLC to detect bulk drug is accordingly: moving phase condition is 20% acetonitrile, 0.1% ammoniacal liquor, formic acid is adjusted pH to 4.90; 25 ℃ of column temperatures; Flow velocity 1.0ml/min; Detect wavelength 210nm; Chromatographic column DiamonsilODS C18 (5 μ m, 250 * 4.6mm) post.
Those skilled in the art are to be understood that, the combination of above-mentioned every HPLC condition can be changed according to actual needs, parameters or parameter area definite in aforementioned 4 factor examination processes can carry out the combination of arbitrary form, and these combinations all should be considered as disclosed content of the present invention.
Determined that HPLC measures after the condition of bulk drug, utilized LC-MS to measure, can determine bulk drug impurity molecule amount.
The LC-MS instrument HPLC Waters 2486 using, MS is WatersmicromassQ-TOF.Chromatographic column is Capcell pak ODS C18 post (5 μ m, 4.6 * 250mm), 25 ℃ of column temperatures, and flow velocity 1.0ml/min, moving phase is 20% acetonitrile, 0.1% ammoniacal liquor, formic acid adjust pH to 4.90.Mass spectrum condition is electron spray ionisation source positive ion detection mode; 80 ℃ of source temperature; Taper hole voltage 35v.After bulk drug is dissolved by moving phase, difference injection liquid matter combined instrument, sample size 10 μ l.
LC-MS measurement result shows, the retention time of main peak is 18.94min, and the time of withing a hook at the end in bulk drug is respectively five impurity of 8.42min, 11.32min, 15.62min, 16.95min, 31.32min.MS collection of illustrative plates shows, [M+H] of five impurity
+m/z is followed successively by 491,585,503,505 and 425.Wherein the impurity molecule amount at retention time 31.32min place is 424, is the synthetic starting raw material clindamycin of Clindamycin Phosphate industry.The retention time of remaining four impurity and molecular weight are respectively 8.42min, 490; 11.32min, 584; 15.62min, 502 and 16.95min, 504, is defined as impurity 1, impurity 2, impurity 3 and impurity 4 successively.
HPLC measures each batch of crude product
According to above four assorted qualitative attributions determining, in bulk drug the total content 1.5% of 4 unknown impurities less than, it is directly separated from bulk drug that to prepare impurity be difficult, therefore utilize HPLC to measure the crude product of bulk drug and five batches, utilize peak area normalization method to measure the content of target impurity, for column chromatography below with prepare mask work guide is provided.
the separated preparation of HPLC method target impurity
In present embodiment, select impurity 3 to be prepared.The molecular weight of impurity 3 is 502, differ 2 with the molecular weight of main peak, chromatogram retention behavior and main peak difference are obvious, its preparation condition is: 22% acetonitrile, and 0.1% ammoniacal liquor, formic acid is adjusted pH to 4.00, flow velocity 1.0ml/min, AgelaVenusil ODS XBP C18 post (5 μ m, 10mm * 250mm) for chromatographic column, sample size 120 μ l.Prepare separate apparatus and select Waters510, detect wavelength 210nm.Use sample aqueous solution is prepared, the about 200mg/ml of concentration.Collect peak approximately 10 pins at retention time 20.590min place, it is 502 that concentrated rear mass spectrum records molecular weight, can determine that this chromatographic peak is impurity 2.
According to above condition, collect after some pins, according to ordinary method, to collecting liquid, carry out aftertreatment, obtain white solid.
The demonstration of HPLC detected result, the retention time of preparing gained sample is consistent with the retention time of impurity in bulk drug 3, has further confirmed that the sample making is impurity 3, and it is more than 95% that HPLC measures its purity.
The Structural Identification of impurity 3
High resolution mass spectrum is measured [M+H]
+mass-to-charge ratio is 503.1386, and it is elementary composition is C
18h
33n
2o
11pSCl, degree of unsaturation is 4, degree of unsaturation is more 1 than Clindamycin Phosphate, shown in associative list 1
1h-NMR (400MHz, D
2o) compose,
13the parsing of C-NMR spectrum, COSY spectrum, hsqc spectrum and HMBC spectrum identifies that its structure is as shown in the formula shown in I:
Table 1: impurity 3
1h-NMR spectrum,
13c-NMR spectrum, COSY spectrum, hsqc spectrum and HMBC spectrum ownership
Impurity 3
13in C-NMR spectrum, 18 carbon signals have been there are, respectively 18 carbon atoms in counter structure.According to chemical shift, δ 169.4 is attributed to C-10, δ
h5.46 (d, 1H, J=6.00Hz) are H-1, δ
h2.11 (s, 3H) are H-9, and 2.86 (s, 3H) are H-5 ', 1.29 (q, 3H) are H-8,0.87 (q, 3H, J=7.20Hz) be H-8 ', according to hsqc spectrum, δ 87.3,22.6,13.5,40.9,13.5 is attributed to respectively C-1, C-8, C-9, C-5 ' and C-8 '.
According to
1h-
1hCOSY spectrum, δ 1.94 (q, 2H, J=7.20Hz) and H-8 ' are relevant, are attributed to H-7 ', and according to HSQC, δ 22.9 is C-7 '.
1h-
1in H COSY spectrum, δ 5.58 (d, 1H, J=7.20Hz) and H-7 ' are correlated with, so δ 5.58 is attributed to H-6 ', and according to HSQC, δ 129.7 is attributed to C-6 ', according to chemical shift δ 127.8, is attributed to C-3 '.In HMBC spectrum, C-3 ' while and δ 2.67 (m, 1H), δ 3.73 (m, 1H) and δ 4.18 (m, 1H), δ in hsqc spectrum
c60.4 while and δ
h3.73, δ
h4.18 is relevant, δ
c32.6 while and δ
h2.67, δ
h3.22 relevant.According to chemical shift, δ 3.73 and δ 4.18 are attributed to H-4 ', and δ 60.4 is attributed to C-4 '; δ
h2.67 and δ
h3.22 are attributed to H-2 ', δ
c32.6 are attributed to C-2 '.
1h-
1in H COSY spectrum, H-2 ' and δ 4.36 (m, 1H) are relevant, so δ 4.36 (m, 1H) is attributed to H-1 ', and according to HSQC, δ 69.2 is attributed to C-1 '.
1h-
1in H COSY spectrum, H-8 and δ 4.60 (m, 1H) are relevant, and δ 4.60 (m, 1H) is attributed to H-7.H-7 and H-8, δ 4.41 (q, 1H) are correlated with, so δ 4.41 (q, 1H) is attributed to H-6.H-6 and δ 4.32 (m, 1H) are relevant, so δ 4.32 (m, 1H) is attributed to H-5.According to HSQC, δ 69.7,53.9,58.8 is attributed to respectively C-5, C-6 and C-7.According to
1h-
1hCOSY spectrum, H-1 and δ 4.41 (q, 1H) are relevant, and δ 4.41 (q, 1H) is attributed to H-2.H-2 is simultaneously relevant with H-1, δ 3.73 (m, 1H), so δ
h3.73 (m, 1H) are attributed to H-3.H-3 is simultaneously relevant with H-2, δ 3.85 (d, 1H, J=2.40Hz), so δ
h3.85 (d, 1H, J=2.40Hz) are attributed to H-4.According to hsqc spectrum, δ 72.0,70.9,68.7 is attributed to respectively C-2, C-3 and C-4.C-2 is owing to being subject in connected phosphate radical
31the coupling of P has produced to be split minute, occurs the swarming that splits of δ 72.1.
Impurity 3 bacteriostatic tests
Get impurity 3 samples of preparing in aforementioned embodiments, because sample adheres in flask walls, the sample estimated weight that spoon is scraped out adds methanol constant volume in volumetric flask, about 1mg/ml.
Adopt antibacterial ring test method to gram-positive microorganism, and the malignant bacteria such as Bacillus subtilus, streptococcus aureus, Candida albicans, intestinal bacteria, resistant organism (MRSA) has carried out bacteriostatic test.Result shows 3 pairs of gram-positive microorganisms of impurity, and Bacillus subtilus, streptococcus aureus etc. present obvious antibacterial ring.And Candida albicans, intestinal bacteria, resistant organism (MRSA) are not presented to antibacterial ring.Hence one can see that impurity 3 is in vitro to gram-positive microorganism, and especially Bacillus subtilus, streptococcus aureus have obvious bacteriostatic action; Candida albicans, intestinal bacteria, resistant organism (MRSA) are not had to resistance.
Claims (7)
1. dehydrogenation Clindamycin Phosphate, its structural formula is as shown in the formula shown in I:
2. the preparation method of dehydrogenation Clindamycin Phosphate as claimed in claim 1, is characterized in that Clindamycin Phosphate raw material to analyze, and the described dehydrogenation Clindamycin Phosphate of separated preparation therefrom, comprises the following steps:
A) by LC-MS method, measure described Clindamycin Phosphate raw material, according to the relative retention time of analyzed composition and/or molecular weight, determine the dehydrogenation Clindamycin Phosphate in described raw material;
B) according to step, the shown chromatogram retention behavior of relative retention time of the dehydrogenation Clindamycin Phosphate described in a) is determined the condition of preparative chromatography, by preparative chromatography, collects and analyzed composition corresponding to described relative retention time;
Wherein, step a) in, it is 4.00～5.00 that described LC-MS method is measured the moving phase pH value adopting; It is 20 ℃～40 ℃ that described LC-MS method is measured the column temperature adopting; Described LC-MS method is measured the moving phase adopting and is comprised 15%～25% acetonitrile; And the moving phase that described LC-MS method mensuration adopts comprises 0.1%～0.3% ammoniacal liquor;
Step b), in, described preparative chromatography institute employing condition comprises:
Moving phase 15%～25% acetonitrile, 0.1～0.3% ammoniacal liquor;
PH formic acid is adjusted pH to 4.00～5.00;
Column temperature: 20 ℃～40 ℃;
Chromatographic column Waters μ Bondapak ODS C18,5 μ m, 7.8mm * 300mm post, or Agela Venusil ODS XBP C18,5 μ m, 10mm * 250mm post.
3. method according to claim 2, is characterized in that, step a) in, described LC-MS method is measured the HPLC condition that adopts and is:
Moving phase 20% acetonitrile, 0.1% ammoniacal liquor;
PH formic acid is adjusted pH to 4.90;
25 ℃ of column temperatures;
Flow velocity 1.0ml/min;
Detect wavelength 210nm;
Chromatographic column Diamonsil ODS C18,5 μ m, 250 * 4.6mm post.
4. method according to claim 3, is characterized in that, step b) in, described preparative chromatography institute employing condition is:
Moving phase 22% acetonitrile, 0.1% ammoniacal liquor;
PH formic acid is adjusted pH to 4.00;
Flow velocity 1.0ml/min;
Detect wavelength 210nm;
Chromatographic column Agela Venusil ODS XBP C18 post, 5 μ m, 10mm * 250mm post;
Sample size 120 μ l;
Collecting retention time is the corresponding assay in peak of locating for 20.220 minutes.
5. dehydrogenation Clindamycin Phosphate as claimed in claim 1 is for the preparation of the purposes of medicament for resisting gram-positive bacteria.
6. purposes as claimed in claim 5, wherein said gram-positive microorganism comprises anti-Bacillus subtilus and streptococcus aureus.
7. dehydrogenation Clindamycin Phosphate as claimed in claim 1 is for analyzing the purposes of Clindamycin Phosphate raw material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910198984.8A CN102060882B (en) | 2009-11-18 | 2009-11-18 | Dehydrogenated clindamycin phosphate, analysis preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910198984.8A CN102060882B (en) | 2009-11-18 | 2009-11-18 | Dehydrogenated clindamycin phosphate, analysis preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102060882A CN102060882A (en) | 2011-05-18 |
| CN102060882B true CN102060882B (en) | 2014-02-19 |
Family
ID=43996402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910198984.8A Active CN102060882B (en) | 2009-11-18 | 2009-11-18 | Dehydrogenated clindamycin phosphate, analysis preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102060882B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103122013B (en) * | 2011-11-18 | 2016-07-06 | 上海医药工业研究院 | Dehydrogenation clindamycin, its analysis preparation method and purposes |
| CN102964401B (en) * | 2012-11-20 | 2015-08-12 | 广州白云山天心制药股份有限公司 | A kind of preparation method of Clindamycin Phosphate |
-
2009
- 2009-11-18 CN CN200910198984.8A patent/CN102060882B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102060882A (en) | 2011-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102062758B (en) | Impurity analysis and preparation method for clindamycin phosphate | |
| CN103123342B (en) | The impurity analysis preparation method of clindamycin | |
| Larsen et al. | Production of mycotoxins by Aspergillus lentulus and other medically important and closely related species in section Fumigati | |
| Tsuchiya et al. | Biosynthetic route towards saxitoxin and shunt pathway | |
| Molyneux et al. | Polyhydroxy alkaloids: chromatographic analysis | |
| Song et al. | Homolog-focused profiling of ginsenosides based on the integration of step-wise formate anion-to-deprotonated ion transition screening and scheduled multiple reaction monitoring | |
| Matselyukh et al. | N-methylphenylalanyl-dehydrobutyrine diketopiperazine, an A-factor mimic that restores antibiotic biosynthesis and morphogenesis in Streptomyces globisporus 1912-B2 and Streptomyces griseus 1439 | |
| CN103743809A (en) | Method for detecting enrofloxacin metabolic products in sea cucumber | |
| Zhang et al. | Qualitative and Quantitative Assessments of Aconiti Lateralis Radix Praeparata Using High-Performance Liquid Chromatography Coupled with Diode Array Detection and Hybrid Ion Trap–Time-of-Flight Mass Spectrometry | |
| CN102060882B (en) | Dehydrogenated clindamycin phosphate, analysis preparation method and application thereof | |
| CN113899834B (en) | Method for detecting nitrosamine impurities in medicine | |
| CN102060883B (en) | Clindamycin phosphate isomer, analysis and preparation method for same and use | |
| Westley et al. | Biosynthesis of lasalocid. III Isolation and structure determination of four homologs of lasalocid A | |
| Hu et al. | Identification of the components of 16-membered macrolide antibiotics by LC/MS | |
| Lacey et al. | Conglobatins B–E: cytotoxic analogues of the C2-symmetric macrodiolide conglobatin | |
| Rawa et al. | Zealpeptaibolin, an 11-mer cytotoxic peptaibol group with 3 Aib-Pro motifs isolated from Trichoderma sp. RK10-F026 | |
| Zhao et al. | Qualitative and quantitative analysis of the diuretic component ergone in Polyporus umbellatus by HPLC with fluorescence detection and HPLC-APCI-MS/MS | |
| Wolf et al. | Burning the hay to find the needle–Data mining strategies in natural product dereplication | |
| Kadam et al. | Cassette analysis of eight beta-blockers in bovine eye sclera, choroid–RPE, retina, and vitreous by liquid chromatography–tandem mass spectrometry | |
| Hanko et al. | Identification of tobramycin impurities for quality control process monitoring using high-performance anion-exchange chromatography with integrated pulsed amperometric detection | |
| Park et al. | The nebramycin aminoglycoside profiles of Streptomyces tenebrarius and their characterization using an integrated liquid chromatography-electrospray ionization-tandem mass spectrometric analysis | |
| CN105486775A (en) | Method for detecting content of various components in pills for treating kidney-yang deficiency | |
| Hoang et al. | Istamycin aminoglycosides profiling and their characterization in Streptomyces tenjimariensis ATCC 31603 culture using high‐performance liquid chromatography with tandem mass spectrometry | |
| Řezanka et al. | Pilot-plant cultivation of Streptomyces griseus producing homologues of nonactin by precursor-directed biosynthesis and their identification by LC/MS-ESI | |
| Liebich et al. | Rapid quantitative microanalysis of ketones in urine by gas chromatography-mass fragmentography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180404 Address after: Fengze Road Chengguan Tiantai County Taizhou city Zhejiang province 317200 No. 588 Patentee after: Zhejiang Tiantai Pharmaceutical Co., Ltd. Address before: 200040 Beijing West Road, Shanghai, No. 1320 Patentee before: Shanghai Institute of pharmaceutical industry |
|
| TR01 | Transfer of patent right | ||
| CP03 | Change of name, title or address |
Address after: No. 588, Fengze Road, Chicheng street, Tiantai County, Taizhou City, Zhejiang Province, 317200 Patentee after: Zhejiang Tiantai Pharmaceutical Co.,Ltd. Address before: 317200 588, Feng Ze Road, Chengguan, Tiantai County, Taizhou, Zhejiang Patentee before: ZHEJIANG TIANTAI PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address |